Schrodinger, Inc.
corporate_fare Company Profile
Schrodinger, Inc. (NASDAQ:SDGR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for SDGR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for SDGR spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Novartis Deal Reworked With $1.42B Milestone Potential as Q3 Revenue Tops Estimates
- Schrödinger 10-Q: Q3 Revenue Up 19% to $64.5M, $373M Cash, Novartis Deal Amended
- Schrödinger Lifts 2026 ACV and Drug Discovery Guidance as Q3 Revenue Grows 19%
- Schrödinger Beats on Revenue Growth, Raises Full-Year ACV and Drug Discovery Outlook
- Schrödinger Co-Founds Tectora with $55M Series A, Contributes Two Immunology Programs
Financial Snapshot
Short Interest & Short Volume
5.82 days to coverFINRA reported short interest of 9,750,213 shares in SDGR as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 35.6% of SDGR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.